Biotech and Pharmaceuticals Medicine

More

  • I Smell A Rat, er, A Blog Wednesday, 7 Oct 2009 | 2:31 PM ET
    rats_200.jpg

    I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day. Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

  • Novartis' Flu Shot Across The Bow Tuesday, 6 Oct 2009 | 1:23 PM ET
    Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Swine Flu By Any Other Name ... Like H1N1 Tuesday, 6 Oct 2009 | 12:59 PM ET

    The pork industry would prefer the media to use the more scientific term but "swine flu" tends to be more reader/viewer friendly.

  • Just Another Manic Monday In Biopharma Monday, 5 Oct 2009 | 11:36 AM ET

    If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.

  • A Race in Cardiology Thursday, 1 Oct 2009 | 1:06 PM ET
    Heart Drawing

    A race is on to develop the potentially next big thing in heart surgery: a replacement valve that can be implanted through thin tubes known as catheters rather than by traditional open-heart surgery.

  • Flu Fears Mean 24/7 Production for Mask Makers Wednesday, 30 Sep 2009 | 9:54 AM ET

    Workers are fighting the flu around the clock at the Alpha Pro Tech factory in Salt Lake City, Utah.

  • H1N1 Vaccine Is Top Flu Concern For U.S. Businesses Wednesday, 30 Sep 2009 | 7:36 AM ET
    New York Public Information Campaign Warns of Swine Flu

    The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.

  • Sequenom Board To CEO: "You're Fired" Tuesday, 29 Sep 2009 | 11:32 AM ET
    Sequenom

    It's the equivalent of slipping a press release with negative news under the door at the close of business on a Friday. But after the closing bell on Yom Kippur, when many people including me were trying to give up food and tweeting for a day, Sequenom tossed a grenade.

  • Dendreon Makes The List...Again Friday, 25 Sep 2009 | 12:44 PM ET

    2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.

  • Do Drugs And Tweets Mix? Wednesday, 23 Sep 2009 | 2:50 PM ET
    Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • The Jury's Out On Dendreon Tuesday, 22 Sep 2009 | 10:41 AM ET
    dendreon.jpg

    It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.

  • No Constipation In Biopharma Newsflow Monday, 21 Sep 2009 | 12:29 PM ET

    When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.

  • pharma_new3.jpg

    Iin light of evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.

  • Arena Adds Volume Friday, 18 Sep 2009 | 1:33 PM ET

    There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • A Rise For Biopharma In The Fall? Wednesday, 16 Sep 2009 | 12:14 PM ET
    cadeuses2.jpg

    Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.

  • Auxilium, Pfizer Could Get A Helping Hand Tuesday, 15 Sep 2009 | 4:51 PM ET

    Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.

  • A Ghost Of A Chance In Pancreatic Cancer Tuesday, 15 Sep 2009 | 12:24 PM ET
    Patrick Swayze

    Patrick Swayze is sadly a statistic. He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year. Several companies are working on drugs for the disease, but the path is littered with failures.

  • Will Pot TV Show Bring 'High' Ratings? Tuesday, 15 Sep 2009 | 10:26 AM ET
    Marijuana

    Tips for cultivating marijuana. Testimonials by patients about its medical benefits. Cannabis cooking lessons. Even citations for award-winning strains of pot. Viewers here can now watch, every week, what amounts to a pro-weed news program.

  • Lilly: 'Let's Get Small'-er Monday, 14 Sep 2009 | 1:41 PM ET
    lilly_hq.jpg

    Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.

  • Mylan Parts Ways With PR Tradition Thursday, 10 Sep 2009 | 9:53 AM ET
    Mylan Laboratories Inc. headquarters

    Usually when a company announces an executive departure the news comes out in a press release with a header along the lines of , "So-and-so to retire, search begins for successor," or, "XYZ Corp. CEO resigns, interim CEO appointed," etc.